<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475042</url>
  </required_header>
  <id_info>
    <org_study_id>19.185</org_study_id>
    <nct_id>NCT04475042</nct_id>
  </id_info>
  <brief_title>Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>STADIA-HFpEF</acronym>
  <official_title>Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction. A 35-week, Single-center, Prospective, Double-blind, Controlled, Randomized, 2x2 Crossover, Interventional Phase II Study, Investigating the Effect of Treatment With Dapagliflozin 10mg od on Left Ventricular Distensibility in Patients With Early HFpEF.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mariëlle Scheffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Onze Lieve Vrouwe Gasthuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 35-week, single-center, prospective, double-blind, controlled, randomized, 2x2 crossover,
      interventional Phase II study, investigating the effect of treatment with dapagliflozin 10mg
      od on Left Ventricular distensibility in patients with early HFpEF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular (LV) e'</measure>
    <time_frame>13 weeks</time_frame>
    <description>echocardiographically measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E/e'/LV end-diastolic volume index</measure>
    <time_frame>13 weeks</time_frame>
    <description>echocardiographically measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial volume</measure>
    <time_frame>13 weeks</time_frame>
    <description>Echocardiographically derived volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic parameters</measure>
    <time_frame>13 weeks</time_frame>
    <description>Echocardiographically derived function, filling and compliance of Left Ventricular</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial function</measure>
    <time_frame>13 weeks</time_frame>
    <description>Echocardiographically derived strain analysis, resevoir, conduit and booster pump function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin - washout period - placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo - washout period - Dapagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10mg od</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years at time of screening

          2. Symptomatic chronic heart failure patients with diagnosis of heart failure and:

               -  NYHA class II-IV

               -  Preserved systolic Left Ventricular (LV) function, defined by: LV Ejection
                  Fraction (LVEF) ≥ 50% and LV end-diastolic volume index &lt;97 ml/m2

               -  Evidence of diastolic LV dysfunction and at least 1 out of the 5 following
                  additional criteria:

                    1. H2FPEF score ≥ 6;

                    2. HFA-PEFF score ≥ 5;

                    3. Pulmonary capillary wedge pressure &gt; 15 mmHg at rest or &gt; 25 mmHg with
                       exercise assessed with right heart catheterization;

          3. Cardiac MRI T1 derived extracellular volume &lt;29% at screening

          4. Oral diuretics, if prescribed to the patient according to local guidelines and at the
             discretion of the investigator, should be stable for at least 1 week prior to baseline
             visit

          5. Signed and dated written informed consent in accordance with GCP and local legislation
             prior to admission to the trial

        Exclusion Criteria:

          1. Reduced systolic LV function (LVEF &lt; 50%), measured at any time point in the history
             of the patient

          2. Obstructive coronary artery disease with evidence of ischemia

          3. Myocardial infarction, coronary artery bypass graft surgery or other major
             cardiovascular surgery, stroke or TIA in past 90 days prior to screening visit

          4. More than mild valve stenosis

          5. More than moderate aortic and/or mitral valve regurgitation

          6. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation
             diseases (e.g. hemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy
             with reversible causes (stress cardiomyopathy), hypertrophic (obstructive)
             cardiomyopathy or known pericardial constriction

          7. History of mitral valve repair or replacement

          8. Atrial fibrillation or atrial flutter with a resting heart rate &gt; 110 bpm at screening

          9. Acute decompensation that requires intravenous loop diuretics

         10. Systolic blood pressure ≥ 180 mmHg. If SBP &gt; 150 mmHg and &lt; 180 mmHg, the patient
             should be receiving at least 3 antihypertensive drugs at screening or baseline visit

         11. Symptomatic hypotension and/or a SBP &lt; 100 mmHg at screening or baseline visit

         12. Impaired renal function, defined as eGFR &lt; 30 ml/min/1.73 m2

         13. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT),
             or alkaline phosphatase above 3x upper limit of normal or history of cirrhosis with
             evidence of portal hypertension

         14. Hemoglobin &lt; 9 g/dl at screening

         15. Chronic obstructive pulmonary disease, more than GOLD class 2

         16. Pulmonary function test with FEV1/FVC &lt; 80%

         17. Primary pulmonary arterial hypertension

         18. Type 1 Diabetes Mellitus

         19. History of ketoacidosis

         20. Any documented active or suspected malignancy or history of malignancy within 2 years
             prior to screening, except appropriately treated basal cell carcinoma of the skin or
             in situ carcinoma of uterine cervix or low risk prostate cancer (biopsy Gleason score
             of ≤ 6 and clinical stage T1c or T2a)

         21. Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor
             within 3 months prior to screening visit. Discontinuation of a SGLT-2 inhibitor or
             combined SGLT-1 and 2 inhibitor for the purposes of study enrolment is not permitted

         22. Pregnancy or lactation

         23. Any (clinical) condition that, in the investigator's opinion, would jeopardize
             patients safety while participating in this trial, or may prevent the patient from
             adhering to the trial protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Onze Lieve Vrouwe Gasthuis</investigator_affiliation>
    <investigator_full_name>Mariëlle Scheffer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

